Silencing survivin results in synergy between methylseleninic acid and paclitaxel against skov3 ovarian cancer cells

Cancer Biology and Therapy

Volumn 7, Issue 12, 2008, Pages 1901-1908

  Azrak, Rami G ^a   Frank, Cheryl L ^a   Ghadersohi, Ali ^a   Rustum, Youcef M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Drug synergy; Methylseleninic acid; Ovarian cancer; Paclitaxel; Skov3; Survivin

Indexed keywords

ANTINEOPLASTIC AGENT; METHYLSELENINIC ACID; PACLITAXEL; SELENIUM DERIVATIVE; SHORT HAIRPIN RNA; SURVIVIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL DEATH; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OVARY CARCINOMA; PROTEIN EXPRESSION; WILD TYPE;

EID: 58149117507     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.12.6939     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Hao Y, Murray T, Xu J, Thun MJ. Cancer Statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
2. Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992; 10:1748-53.
3. Runowicz CD, Wiernik PH, Einzig AI, Goldberg GL, Horwitz SB. Taxol in ovarian cancer. Cancer 1993; 71:1591-6.
4. Ozols RF. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer. Semin Oncol 2000; 27:3-7.
5. Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, de Swart CA, Hirsch FR, Lund B, van Houwelingen HC. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000; 18:3084-92.
6. Rowinsky EK, Donehower RC. Paclitaxel (taxol) [erratum appears in N Engl J Med 1995; 333:75]. N Engl J Med 1995; 332:1004-14.
7. Horwitz SB. Mechanism of action of taxol. Trends Pharmocol Sci 1992; 13:134-6.
8. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002; 2:1-17.
9. Du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J, Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95:1320-9.
10. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R, Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21:3194-200.
11. Ip C, Dong Y, Ganther HE. New concepts in selenium chemoprevention. Cancer Met Reviews 2002; 21:281-9.
12. Ip C, Thompson HJ, Zhu Z, Ganther HE. In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 2000; 60:2882-6.
13. Jiang C, Wang Z, Ganther H, Lu J. Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res 2001; 61:3062-70.
14. 1 arrest by selenium metabolite methylselenol. Mol Carcinog 2002; 34:113-20.
15. Lu J. Apoptosis and angiogenesis in cancer prevention by selenium. Adv Exp Med Biol 2001; 492:131-45.
16. Ip C, Dong Y. Methylselenocysteine modulates proliferation and apoptosis biomarkers in premalignant lesions of the rat mammary gland. Anticancer Res 2001; 21:863-7.
17. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82:1107-12.
18. Azrak RG, Frank CL, Ling X, Slocum HK, Li F, Foster BA, Rustum YM. The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells. Mol Cancer Ther 2006; 5:2540-8.
19. Banasiak D, Barnetson AR, Odell RA, Mameghan H, Russell PJ. Comparison between the clonogenic, MTT, and SRB assays for determining radiosensitivity in a panel of human bladder cancer cell lines and a ureteral cell line. Radiat Oncol Investig 1999; 7:77-85.
20. Cohen SN, Chang AC, Hsu L. Nonchromosomal antibiotic resistance in bacteria: genetic transformation of Escherichia coli by R-factor DNA. Proc Natl Acad Sci USA 1972; 69:2110-4.
21. Sambrook J, Fritsch Ef, Maniatis T. Molecular cloning. A laboratory manual; Cold Spring Harbor, New York 1989.
22. Ghadersohi A, Pan D, Fayazi Z, Hicks DG, Winston JS, Li F. Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo. Breast Cancer Res Treat 2007; 102:19-30.
23. Faessel HM, Levasseur LM, Slocum HK, Greco WR. Precision and pattern in 96-well plate cell growth experiments. Proc Am Stat Assoc Biopharm 1995; 227-32.
24. Faessel HM, Slocum HK, Jackson RC, Boritzki TJ, Rustum YM, Nair MG, Greco WR. Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: the critical role of polyglutamylation. Cancer Res 1998; 58:3036-50.
25. Faessel HM, Levasseur LM, Slocum HK, Greco WR. Parabolic growth patterns in 96-well plate cell growth experiments. In Vitro Cell Dev Biol Anim 1999; 35:270-8.
26. Levasseur LM, Greco WR, Rustum YM, Slocum HK. Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells. Cancer Chemother Pharmocol 1997; 40:495-505.
27. Cao S, Durrani F, Rustum YM. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res 2004; 10:2561-9.
28. Hu H, Jiang C, Ip C, Rustum YM, Lu J. Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells. Clin Cancer Res 2005; 11:2379-88.
29. Vadgama JV, Wu Y, Shen D, Hsia S, Block J. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells. Anticancer Res 2000; 20:1391-414.
30. Cohen C, Lohmann CM, Cotsonis G, Lawson D, Santoianni R. Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Modern Pathology 2003; 16:574-83.
31. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 2007; 28:1133-9.
32. Tetsuhiro T, Fumitake H, Toshihiko T, Tomohisa F, Satomi I, Takehiro K, Masaaki Y, Atsuhito Y, Tosei O, Koji Y, Tadashi K, Takahiro Y, Kazuaki S, Yasuhiro M, Hidetoshi M, Hiromichi K, Morifumi A, Yoshihiko H, Hiroko A, Yasuaki T, Kumiko S, Noriyuki S, Koichi H. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Medicine 2004; 2:19-29.
33. Tetsuhiro T, Yuji I, Tosei O, Tadashi K, Fumitake H, Tomohisa F, Koji Y, Yasutoshi K, Toshihiko T, Nobuhiko T, Atsuhito Y, Yoshihiko H, Hiroko A, Minoru O, Yasuhiro M, Naohiro N, Noriyuki S, Koichi H. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J Transl Medicine 2008; 6:24-35.